Mindfulness-based cognitive therapy was shown to reduce headache-related disability and disability related to migraine attack-level in adult patients with migraine.
Lipophilic angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may effectively reduce migraine frequency.
BoNT-A showed significant improvements in the frequency and severity of photophobia and eye discomfort.
The FDA has approved Reyvow for the acute treatment of migraine with or without aura in adults.
Tosymra (sumatriptan; Upsher Smith Laboratories) Nasal Spray is now available for the acute treatment of migraine with or without aura in adults.
Researchers have proposed an update to the International Classification of Headache Disorders-3 criteria for headache attributed to transient ischemic attacks.
Fremanezumab, administered once monthly or once quarterly, is associated with greater reductions in monthly average migraine days than placebo in patients with difficult-to-treat migraine who did not respond to ≥2 of 4 classes of migraine preventative medications.
Telemedicine delivered over 1 year to patients with severe migraine-related disability was comparable to in-office visits for improving migraine disability, number of headache days, and average headache severity at 12 months.
Emerging findings suggest that cervical noninvasive vagus nerve stimulation using the gammaCore device may represent an option with efficacy comparable to that of surgically implanted cervical vagus nerve stimulation, with a lower risk for side effects.
A study highlights predictors of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).
